Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-12-10

Clinical Trial Update: GKT137831 in IPF Patients with Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial of GKT137831 in idiopathic pulmonary fibrosis has completed, per the update from the University of Alabama at Birmingham.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Setanaxib (GKT137831)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED